NEW YORK, NY / ACCESSWIRE / May 25, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
AbbVie Inc. (NYSE:ABBV)
CONTACT JAKUBOWITZ ABOUT ABBV:
https://claimyourloss.com/securities/abbvie-inc-loss-submission-form/?id=27743&from=1
Class Period: April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
CONTACT JAKUBOWITZ ABOUT AXSM:
https://claimyourloss.com/securities/axsome-therapeutics-inc-loss-submission-form/?id=27743&from=1
Class Period: December 30, 2019 - April 22, 2022
Lead Plaintiff Deadline: July 12, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Okta, Inc. (NASDAQ:OKTA)
CONTACT JAKUBOWITZ ABOUT OKTA:
https://claimyourloss.com/securities/okta-inc-loss-submission-form/?id=27743&from=1
Class Period: March 5, 2021 - March 22, 2022
Lead Plaintiff Deadline: July 19, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Okta had inadequate cybersecurity controls; (ii) as a result, Okta's systems were vulnerable to data breaches; (iii) Okta ultimately did experience a data breach caused by a hacking group, which potentially affected hundreds of Okta customers; (iv) Okta initially did not disclose and subsequently downplayed the severity of the data breach; (v) all the foregoing, once revealed, was likely to have a material negative impact on Okta's business, financial condition, and reputation; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law